IRadimed

IRadimed FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of IRadimed (IRMD) as of Oct 10, 2026 is 76.43 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 91.61 % — a change of -16.56% (lower).

FCF Conversion

76.43 %

YoY

-16.56%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of IRadimed is 2025 76.43 % . FCF Conversion Rate (FCF/EBITDA) of IRadimed was 2024 91.61 % . It decreases by -16.56% lower compared to the previous year.

The IRadimed FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
112.82 USD
Jan 1, 2019
101.20 USD
Jan 1, 2020
378.43 USD
Jan 1, 2021
112.77 USD
Jan 1, 2022
63.67 USD
Jan 1, 2023
31.74 USD
Jan 1, 2024
91.61 USD
Jan 1, 2025
76.43 USD
The IRadimed FCF Conversion history
YEARFCF ConversionYoY
76.43 %-16.56%
91.61 %+188.57%
31.74 %-50.14%
63.67 %-43.54%
112.77 %-70.20%
378.43 %+273.93%
101.20 %-10.29%
112.82 %-78.24%
518.48 %+374.57%
109.25 %+12.16%
97.40 %+0.90%
96.54 %—
Access this data via the Eulerpool API

IRadimed Stock analysis

What does IRadimed do? IRadimed Corp is an American company specializing in the development, manufacturing, and marketing of advanced medical technology products. The company was founded in 1992 and is headquartered in Winter Springs, Florida. It was founded to meet the need for advanced and precise medical devices used in intensive care. In recent years, the company has focused on the development of components and accessory products for magnetic resonance imaging (MRI) used in radiology and oncology. IRadimed Corp is known for its innovative and technologically advanced approach to the medical technology industry. The company prioritizes research and development and collaborates closely with clinics, hospitals, and medical facilities to provide the best solutions for patient care. It has a strong distribution network that allows its products to be distributed worldwide, particularly in the United States, Europe, and Asia. The company offers a wide range of medical devices and accessory products used in radiology, oncology, and other medical fields. Its specialty lies in manufacturing components and accessories for MRI. These include MRI-compatible infusion pumps, patient monitoring devices, ventilation devices, and coil arrays designed for imaging the skull and spine, as well as breast and prostate imaging. In summary, IRadimed Corp is a leading provider of medical devices and accessories for radiology, oncology, and other specialized fields. Its focus on MRI-compatible devices and accessories, as well as its collaborative approach with medical facilities, sets it apart in the industry. The company prides itself on innovation and technological advancement, offering a wide range of products tailored to the needs of patients and medical professionals. IRadimed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IRadimed stock

FCF Conversion Rate (FCF/EBITDA) of IRadimed is 76.43 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of IRadimed changed from 91.61 % to 76.43 %, representing a -16.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) IRadimed since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s IRadimed with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — IRadimed

All Key Metrics — IRadimed